Exact Sciences Cor EXAS

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: $PRPO ) reported record quarterly revenue of $7.3M for the third quarter ended September 30, 2026, up 8% year-over-year from $6.8M in Q3-2025. Precipio also reported positive Adjusted EBITDA, a non-GAAP measure, and strong operating cash flow, with additional results in its Form 10-Q filed on November 10, 2026. Precipio, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/precipio-inc Both revenue lines grew year-over-year, Adjusted EBITDA stayed positive, and the quarter closed with a larger cash balance than a year earlier: • Product revenue was $1.0M, up 40% year-over-year from $0.7M in Q3-2025 • Pathology revenue was $6.3M, up 5% year-over-year from $6.0M in Q3-2025 • Adjusted EBITDA, a non-GAAP measure, was a positive $0.4M • Cash flow from operations was $0.6M, and total cash increased by $0.5M, resulting in an end-of-quarter cash balance exceeding $3.5M, vs $2.3M in Q3-2025 Ilan Danieli, Chief Executive Officer of Precipio, commented on the company's third-quarter performance in the announcement. “In the third quarter we continued to strengthen our financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations,” said Danieli. Read the full release: https://www.precipiodx.com/precipio-announces-q3-2026-financial-results/ Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in its laboratory where it designs, tests, validates, and uses these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scale Precipio’s reach to eradicate misdiagnosis. More information is available at https://www.precipiodx.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $EXAS, $NTRA, $GH, $XBI

$VCYT remember $EXAS dropped to 40 dollars and $ABT came in at $105

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: $PRPO ) will be hosting its Q3-2026 shareholder update call on November 10, 2026, at 5:00 PM ET. The call will include remarks on the Company’s current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. Precipio, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/precipio-inc-1 This call will incorporate a dedicated moderated live Q&A session into its quarterly update, and listeners can join by phone, send questions in advance, or access the replay: • The conference call may be accessed by calling 646.307.1865, and all callers should ask for the Precipio Inc. conference call • Following Ilan Danieli’s remarks, the moderator will invite listeners to log into the Q&A system, where they will need to identify themselves and the organization they represent (or individual investor) • Listeners interested in submitting questions in advance can email them to [email protected] • A replay will be available approximately 24 hours after the call via the Investors page at https://www.precipiodx.com/investors/ Management looks forward to addressing investor questions and providing additional insight into the Company’s performance, strategy, and growth initiatives. “This quarter, our continued revenue growth was strengthened by Products Division revenues exceeding an important milestone, which we will share in our upcoming shareholder call. As this is also the last shareholder call for the year, we will be sharing some thoughts about where we envision 2027 and beyond taking us”, said Ilan Danieli, CEO. Read the full release: https://www.precipiodx.com/precipio-announces-q3-2026-shareholder-update-call/ Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in its laboratory where it designs, tests, validates, and uses these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis. More information is available at https://www.precipiodx.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $EXAS, $NTRA, $GH, $XBI

$LUCD Being able to buy this at these prices is like having a time machine and being able to go back and scoop up $EXAS at the same lows with prescience of the future. I bought EXAS for an average under $4 and sold it north of $25. I won't make the mistake of selling $LUCD early, this is going to be a hold until triple digit share prices. 500k shares long at 0.68, not selling until over $100.

$HUMA $EXAS sold for $105/share with a smaller potential market cap. Just sayin.

$BLGO The decline is depressing. The opportunity isn’t. 🔥 Clyra’s launch was delayed—not canceled. It doesn’t rely on BLGO to succeed or get financed. The consumer odor product launch is coming soon. Way better terms than they have had with POOPH. And the “Gorilla” partner launch will change everything. 🚀 People mocked my $EXAS conviction all the way to the lows. Then came a 2,000%+ rebound. Different company, but the disconnect between price and potential feels familiar. Could BLGO dip lower? Sure. Timing remains a bit uncertain. But I believe many will regret not adding or averaging down here once execution replaces anticipation. 📈 I’m adding - almost daily. Patience now. Conviction throughout. 💪

$CAI I’m deep 6 figures on this one especially the fact they are proving to be more effective in detecting stage 1 and 2 without symptoms/imagery than any other company. Do your own due diligence and decide for yourself. $GRAL $GH $EXAS $NTRA https://youtu.be/DpkBOG-DAh8?is=lrSaKi4z9w2AR3fS

$HUMA 🔹 Scott Coward: EVP/Chief Legal Officer at Exact Sciences 2015–2022 (the Cologuard ramp), led the Genomic Health integration, and sat on the $EXAS board until Abbott bought it at $105/share in March 2026. Now joins HUMA's Audit Committee. 🔹 Paul Kuznik: 20+ yrs at Abbott Vascular & Diagnostics, then CEO of Bolton Medical (sold to Terumo), then ran Terumo Aortic North America. West Point grad. Joins the Commercial Committee. His Form 3 shows ~222K shares already owned before joining. 🔗 The connections: Chair Kathleen Sebelius also served on the Exact Sciences board alongside Coward. Kuznik is an Abbott veteran, and Abbott is the company that acquired Exact. Coward watched EXAS go from ~$25 to a $4.67 low to a $105 buyout. Kuznik knows how to sell vascular devices to vascular surgeons. That's the playbook HUMA needs for the dialysis launch.